These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 20142282)
1. Pediatric uptake of a newly available antipsychotic medication. Penfold RB; Kelleher KJ; Wang W; Strange B; Pajer K Pediatrics; 2010 Mar; 125(3):475-82. PubMed ID: 20142282 [TBL] [Abstract][Full Text] [Related]
2. Naturalistic study of intramuscular ziprasidone versus conventional agents in agitated elderly patients: retrospective findings from a psychiatric emergency service. Kohen I; Preval H; Southard R; Francis A Am J Geriatr Pharmacother; 2005 Dec; 3(4):240-5. PubMed ID: 16503319 [TBL] [Abstract][Full Text] [Related]
3. Agitation and/or aggression after traumatic brain injury in the pediatric population treated with ziprasidone. Clinical article. Scott LK; Green R; McCarthy PJ; Conrad SA J Neurosurg Pediatr; 2009 Jun; 3(6):484-7. PubMed ID: 19485732 [TBL] [Abstract][Full Text] [Related]
4. [Off-label use of psychotropic medications in pediatric wards: a prospective study]. Winterfeld U; Le Heuzey MF; Acquaviva E; Mouren MC; Brion F; Bourdon O Arch Pediatr; 2009 Sep; 16(9):1252-60. PubMed ID: 19640689 [TBL] [Abstract][Full Text] [Related]
5. Off-label antidepressant use in children and adolescents compared with young adults: extent and level of evidence. Czaja AS; Valuck R Pharmacoepidemiol Drug Saf; 2012 Sep; 21(9):997-1004. PubMed ID: 22760843 [TBL] [Abstract][Full Text] [Related]
6. Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial. Ratner Y; Gibel A; Yorkov V; Ritsner MS Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1401-9. PubMed ID: 17669574 [TBL] [Abstract][Full Text] [Related]
8. A prospective open-label treatment trial of ziprasidone monotherapy in children and adolescents with bipolar disorder. Biederman J; Mick E; Spencer T; Dougherty M; Aleardi M; Wozniak J Bipolar Disord; 2007 Dec; 9(8):888-94. PubMed ID: 18076539 [TBL] [Abstract][Full Text] [Related]
9. Off-label medication use in an academic hospital pediatric critical care unit. Hsu B; Brazelton T WMJ; 2009 Oct; 108(7):343-8. PubMed ID: 19886581 [TBL] [Abstract][Full Text] [Related]
10. Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol. Corripio I; Catafau AM; Perez V; Puigdemont D; Mena E; Aguilar Y; Carrió I; Alvarez E Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jan; 29(1):91-6. PubMed ID: 15610950 [TBL] [Abstract][Full Text] [Related]
11. [Quetiapine and ziprasidone in the treatment of the psychotic disorders in Parkinson's disease]. López del Val LJ; Santos S Rev Neurol; 2004 Oct 1-15; 39(7):661-7. PubMed ID: 15490355 [TBL] [Abstract][Full Text] [Related]
13. Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study. Blair J; Scahill L; State M; Martin A J Am Acad Child Adolesc Psychiatry; 2005 Jan; 44(1):73-9. PubMed ID: 15608546 [TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamics of ziprasidone in children and adolescents: impact on dopamine transmission. Sallee FR; Gilbert DL; Vinks AA; Miceli JJ; Robarge L; Wilner K J Am Acad Child Adolesc Psychiatry; 2003 Aug; 42(8):902-7. PubMed ID: 12874491 [TBL] [Abstract][Full Text] [Related]
15. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003. Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R; Valuck RJ Clin Ther; 2007 Jan; 29(1):183-95. PubMed ID: 17379060 [TBL] [Abstract][Full Text] [Related]
16. New users of antipsychotic medications among children enrolled in TennCare. Cooper WO; Hickson GB; Fuchs C; Arbogast PG; Ray WA Arch Pediatr Adolesc Med; 2004 Aug; 158(8):753-9. PubMed ID: 15289247 [TBL] [Abstract][Full Text] [Related]
17. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial. Gibel A; Ritsner MS Clin Neuropharmacol; 2008; 31(4):204-20. PubMed ID: 18670244 [TBL] [Abstract][Full Text] [Related]
20. Management of acute undifferentiated agitation in the emergency department: a randomized double-blind trial of droperidol, ziprasidone, and midazolam. Martel M; Sterzinger A; Miner J; Clinton J; Biros M Acad Emerg Med; 2005 Dec; 12(12):1167-72. PubMed ID: 16282517 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]